Thursday, April 18, 2024 4/18/2024

The Comparative Effectiveness and Safety of Pharmacotherapies for the Treatment of Opioid Use Disorder in Pregnancy

Award Number: R01DA049822
ORGANIZATION: NATIONAL INSTITUTE ON DRUG ABUSE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Group Awards By Issue Date FY or Funding FY:

View Award Abstract

ABSTRACT With rising rates of opioid use disorder (OUD) in pregnancy, overdose and other complications of OUD have become an increasingly important source of maternal mortality. The postpartum period is a time of particular vulnerability for overdose and other causes of OUD related mortality, but the causes and risk factors for this have not been fully elucidated. Opioid use relapse during the postpartum period may be due to the stresses of new motherhood, loss of insurance, discontinuation of OUD treatment, and opioid analgesic exposure at the time of delivery leading to persistent opioid use and misuse, but data are few. Further, women with OUD may also be particularly vulnerable to other causes of death during the postpartum period including obstetrical complications, suicide, and homicide. There is a need to systematically identify modifiable risk factors that can be the focus of policy and quality improvement initiatives Our group has pioneered the use of pregnancy cohorts nested in the nationwide Medicaid Analytic eXtract (MAX) database to study the safety of medications in pregnancy. The MAX is derived from healthcare utilization claims submitted to the Centers for Medicare and Medicaid Services from all states and Washington, DC. The MAX contains information on patient demographics, inpatient and outpatient diagnoses and procedures, and filled outpatient prescriptions. In the proposed study, we will link the MAX with the National Death Index (NDI), which contains information derived from death certificates including the cause of death. We will then use the linked MAX-NDI database to study the frequency, timing, causes, and risk factors for overdose death and non-overdose deaths in women with OUD. We have assembled an experienced team with extensive expertise in epidemiology, causal inference, substance use disorder, and obstetrics to create this data resource and carry out the proposed Aims. This will not only provide new insight into the epidemiology of overdose and OUD related postpartum death, but also create a powerful new data resource to study maternal mortality generally.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2023 ( Subtotal = $688,134 )
2023	2023	BRIGHAM & WOMENS HOSPITAL INC	75 FRANCIS ST	BOSTON	MA	02115	SUFFOLK	USA	Drug Abuse and Addiction Research Programs	001	4	1/13/2023	NON-COMPETING CONTINUATION	$68,813
2023	2023	BRIGHAM & WOMENS HOSPITAL INC	75 FRANCIS ST	BOSTON	MA	02115	SUFFOLK	USA	Drug Abuse and Addiction Research Programs	000	4	12/22/2022	NON-COMPETING CONTINUATION	$619,321
														Subtotal = $688,134

Issue Date FY: 2022 ( Subtotal = $688,134 )
2022	2022	BRIGHAM AND WOMEN'S HOSPITAL, INC., THE	75 FRANCIS ST	BOSTON	MA	02115	SUFFOLK	USA	Drug Abuse and Addiction Research Programs	000	3	12/8/2021	NON-COMPETING CONTINUATION	$619,320
2022	2022	BRIGHAM AND WOMEN'S HOSPITAL, INC., THE	75 FRANCIS ST	BOSTON	MA	02115	SUFFOLK	USA	Drug Abuse and Addiction Research Programs	001	3	3/25/2022	NON-COMPETING CONTINUATION	$68,814
														Subtotal = $688,134

Issue Date FY: 2021 ( Subtotal = $701,082 )
2021	2021	BRIGHAM AND WOMEN'S HOSPITAL, INC., THE	75 FRANCIS ST	BOSTON	MA	02115	SUFFOLK	USA	Drug Abuse and Addiction Research Programs	000	2	12/15/2020	NON-COMPETING CONTINUATION	$630,973
2021	2021	BRIGHAM AND WOMEN'S HOSPITAL, INC., THE	75 FRANCIS ST	BOSTON	MA	02115	SUFFOLK	USA	Drug Abuse and Addiction Research Programs	001	2	3/2/2021	NON-COMPETING CONTINUATION	$70,109
														Subtotal = $701,082

Issue Date FY: 2020 ( Subtotal = $1,006,296 )
2020	2020	BRIGHAM AND WOMEN'S HOSPITAL, INC., THE	75 FRANCIS ST	BOSTON	MA	02115	SUFFOLK	USA	Drug Abuse and Addiction Research Programs	001	1	4/24/2020	NEW	$0
2020	2020	BRIGHAM AND WOMEN'S HOSPITAL, INC., THE	75 FRANCIS ST	BOSTON	MA	02115	SUFFOLK	USA	Drug Abuse and Addiction Research Programs	002	1	8/28/2020	SUPPLEMENT FOR EXPANSION	$268,441
2020	2020	BRIGHAM AND WOMEN'S HOSPITAL, INC., THE	75 FRANCIS ST	BOSTON	MA	02115	SUFFOLK	USA	Drug Abuse and Addiction Research Programs	000	1	3/26/2020	NEW	$737,855
														Subtotal = $1,006,296

Grand Total All Awards = $3,083,646

Top

All Categories

About

Search

Reports

Data Submission

Award Information

The Comparative Effectiveness and Safety of Pharmacotherapies for the Treatment of Opioid Use Disorder in Pregnancy

Award Number: R01DA049822

ORGANIZATION: NATIONAL INSTITUTE ON DRUG ABUSE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer